TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TLX - TELIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.3
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$19.22

25 Jul
2024

0.370

OPEN

$18.84

1.96%

HIGH

$19.51

2,697,741

LOW

$18.48

TARGET
$24.30 26.4% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TLX: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 1.6 25.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 77.3 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx1.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx502.5 M
Book Value Per Share xxxxxxxxxxxxxxx46.0
Net Operating Cash Flow xxxxxxxxxxxxxxx23.9 M
Net Profit Margin xxxxxxxxxxxxxxx1.04 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx4.55 %
Return on Invested Capital xxxxxxxxxxxxxxx4.09 %
Return on Assets xxxxxxxxxxxxxxx1.57 %
Return on Equity xxxxxxxxxxxxxxx4.55 %
Return on Total Capital xxxxxxxxxxxxxxx40.12 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx14.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx16 M
Total Debt xxxxxxxxxxxxxxx17 M
Goodwill - Gross xxxxxxxxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx123 M
Price To Book Value xxxxxxxxxxxxxxx21.91

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx10.8 M
Capex % of Sales xxxxxxxxxxxxxxx2.15 %
Cost of Goods Sold xxxxxxxxxxxxxxx188 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx263 M
Research & Development xxxxxxxxxxxxxxx129 M
Investments - Total xxxxxxxxxxxxxxx12 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

18/07/2024

1

Buy

$26.00

35.28%

In a first impression by UBS of today's 2Q trading update by Telix Pharmaceuticals, the broker notes an around 11% beat against the consensus estimate for sales of the prostate cancer diagnostic.

Additionally, management's FY24 guidance was raised by 10% at the mid-point to between $745-776m when consensus was expecting $715m, according to the broker (which was predicting $781m).

New guidance implies to UBS sequential growth for Illuccix throughout the year, which is seen as possible given the rapid expansion in the market for PSMA PET scans.

Buy. Target $26.

FORECAST
UBS forecasts a full year FY24 dividend of 0.00 cents and EPS of 21.00 cents.
UBS forecasts a full year FY25 dividend of 0.00 cents and EPS of 28.00 cents.
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

11/06/2024

1

Buy

$16.62

-13.53%

Jarden raises Telix Pharmaceuticals' target price to $16.62 from $13.94 after the company announced favourable radiographic progression-free survival of 8.8 months in its prostate trial.

The trial is not designed to prove efficacy, but Jarden says it is encouraging nevertheless, and increases the company's Phase 3 trial's likely success rating to 60% from 40%.

EPS forecasts are steady. Buy rating retained.

FORECAST
Jarden forecasts a full year FY24 dividend of 0.00 cents and EPS of 19.90 cents.
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 38.30 cents.
Access Stockbroker Research History >

TLX STOCK CHART

FNArena News on TLX

1
Next Week At A Glance – 29 Jul-2 Aug 2024

Jul 26 2024 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Jul 25, 2024

Jul 25 2024 - Daily Market Reports
3
Rudi’s View: How To Invest Allan’s $300k, Part 2

Jul 25 2024 - Rudi's View
4
Next Week At A Glance – 22-26 July 2024

Jul 19 2024 - Weekly Reports
5
Rudi’s View: Rate Cuts, Growth & Small Caps

Jul 18 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Shares Breaking Free

Jul 23 2024 - Technicals
2
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
3
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
4
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
6
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
7
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
8
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
9
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
10
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps